Skip to main content
DXCM
NASDAQ Industrial Applications And Services

Dexcom Q2 Revenue Jumps 13% to $1.31B, Operating Income Surges 50%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$80.39
Mkt Cap
$28.763B
52W Low
$54.11
52W High
$89.98
52W Position info
49% above low
Off High info
11% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

DXCM sits 49% above its 52-week low of $54.11.

Summary

Dexcom reported Q2 2026 revenue of $1.31 billion, up 13% year-over-year, with operating income surging 50% to $318 million. Gross margins expanded to 63.4%, and the company repurchased $600 million in stock.


Key Events · Earnings and Guidance · DXCM

  • Revenue Growth Accelerates

    Q2 revenue reached $1.308 billion, a 13% increase year-over-year, driven by 11% U.S. growth and 19% international growth. The company added approximately 600,000 to 700,000 net new customers in 2025, fueling sensor volume growth.

  • Profitability Surges

    GAAP operating income jumped 50% to $318.3 million, with operating margin expanding to 24% from 18% a year ago. Net income rose 39% to $249.1 million, or $0.64 per diluted share.

  • Gross Margin Expansion

    Gross margin improved to 63.4% from 59.5%, driven by G7 15 Day benefits, improved manufacturing efficiencies, and higher production volumes, partially offset by higher inventory reserve charges related to G6 discontinuation.

  • Aggressive Share Repurchases

    Dexcom repurchased 8.6 million shares for $600 million during the quarter under a new $1 billion buyback program authorized in May 2026. The company ended the quarter with $1.95 billion in cash and marketable securities.


Analysis · DXCM · Industrial Applications And Services

A standout quarter for Dexcom saw revenue growth accelerate to 13% year-over-year, fueled by robust U.S. and international demand for its G7 and Stelo CGM systems. Gross margin expanded sharply to 63.4%, reflecting manufacturing efficiencies and the benefits of the G7 15 Day sensor. Operating income surged 50%, demonstrating significant operating leverage. The balance sheet remains fortress-like with $1.95 billion in cash and no borrowings, while management deployed $600 million to repurchase 8.6 million shares under a new $1 billion buyback program. These results reinforce Dexcom's leadership in the rapidly growing CGM market and its ability to convert top-line growth into substantial profitability.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DXCM was trading at $80.39 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $28.8B. The 52-week trading range was $54.11 to $89.98. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DXCM - Latest Insights

DXCM
Oct 29, 2026, 5:22 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $81.30
Real-time Price: $83.31 info
Change: +$2.01 (+2%) info
Market Cap: $31.078B info
DXCM
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $79.20
Real-time Price: $83.31 info
Change: +$4.11 (+5%) info
Market Cap: $31.078B info
DXCM
Oct 29, 2026, 4:03 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $79.93
Real-time Price: $83.31 info
Change: +$3.38 (+4%) info
Market Cap: $31.078B info
DXCM
Oct 15, 2026, 10:04 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $87.85
Real-time Price: $83.31 info
Change: -$4.54 (-5%) info
Market Cap: $31.078B info
DXCM
Jul 30, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $79.00
Real-time Price: $83.31 info
Change: +$4.31 (+5%) info
Market Cap: $31.078B info